Kura Oncology Inc
KURAHealthcare|Biotechnology|USA
$11.44
-0.63 (-5.22%)
Tangible Book
$1.22
Earnings Power
$4.33
Financials
Financial Snapshot
Market Cap
$1.02B
Enterprise Value
$556.5M
Revenue (TTM)
$71.6M
Net Income (TTM)
$-294.6M
Cash & Equivalents
—
Net Cash/Share
$0.41
Free Cash Flow (TTM)
$-84.5M
Operating CF (TTM)
$-78.0M
Debt/Equity
0.23
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$19.5M
Monthly Burn
$6.5M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $67.8M | $93.1M | $179.0M | $236.9M | $633.3M | $518.0M | $438.0M | $424.0M | $727.4M | $667.2M | $580.8M | |
| Operating Cash Flow | $-25.3M | $-28.4M | $-48.7M | $-54.8M | $-69.8M | $-104.6M | $-110.1M | $-124.8M | $134.3M | $-64.1M | $-78.0M | |
| Free Cash Flow | $-25.3M | $-28.4M | $-48.7M | $-54.8M | $-72.0M | $-105.7M | $-110.7M | $-125.0M | $133.8M | $-70.7M | $-84.5M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $-2.2M | $-1.1M | $-626.0K | $-168.0K | $-472.0K | $-6.6M | $-6.5M | |
| Financing Cash Flow | $7.5M | $53.6M | $132.6M | $111.1M | $469.3M | $-3.4M | $38.6M | $94.8M | $154.4M | $1.8M | $1.7M |
R&D Spending
R&D (TTM)
$260.4M
R&D Intensity
363.4%
R&D Growth YoY
+3.7%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $53.9M | $67.5M | $71.6M | |
| R&D Expense | $16.6M | $26.4M | $46.8M | $47.8M | $60.4M | $84.7M | $92.8M | $115.2M | $170.0M | $251.1M | $260.4M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | 315.4% | 372.1% | 363.4% | |
| SG&A | $8.0M | $9.7M | $16.1M | $19.7M | $31.5M | $46.5M | $47.1M | $50.6M | $77.1M | $120.0M | $128.7M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $53.9M | $67.5M | $71.6M | |
| Cost of Goods Sold | $3.8M | $1.3M | $1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $57.0K | $262.0K | |
| Gross Profit | $-3.8M | $-1.3M | $-1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $53.9M | $67.4M | $71.4M | |
| R&D | $16.6M | $26.4M | $46.8M | $47.8M | $60.4M | $84.7M | $92.8M | $115.2M | $170.0M | $251.1M | $260.4M | |
| SG&A | $8.0M | $9.7M | $16.1M | $19.7M | $31.5M | $46.5M | $47.1M | $50.6M | $77.1M | $120.0M | $128.7M | |
| Operating Income | $-28.4M | $-36.1M | $-62.9M | $-67.5M | $-91.9M | $-131.3M | $-139.9M | $-165.8M | $-193.2M | $-303.6M | $-317.7M | |
| Interest Expense | $-577.0K | $-888.0K | $-970.0K | $-580.0K | $-578.0K | $-414.0K | $-229.0K | $-1.5M | $-1.6M | $-1.5M | $-1.5M | |
| Pretax Income | $-27.6M | $-35.4M | $-60.4M | $-63.1M | $-89.6M | $-130.5M | $-135.8M | $-152.6M | $-172.0M | $-278.4M | $-294.5M | |
| Net Income | $-27.6M | $-35.4M | $-60.4M | $-63.1M | $-89.6M | $-130.5M | $-135.8M | $-152.6M | $-174.0M | $-278.7M | $-294.6M | |
| EPS (Diluted) | -1.47 | -1.52 | -1.72 | -1.51 | -1.69 | -1.97 | -2.03 | -2.08 | -2.02 | -3.18 | -3.35 | |
| EBITDA | $-27.0M | $-34.5M | $-59.5M | $-62.6M | $-88.9M | $-129.5M | $-134.9M | $-150.2M | $-169.5M | $-275.8M | $-291.9M | |
| Shares Out. (M) | 18.70 | 23.24 | 35.19 | 41.95 | 53.08 | 66.35 | 66.99 | 73.23 | 86.16 | 87.68 | 88.61 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.7M | $11.4M | $16.1M | $26.1M | $325.5M | $90.7M | $51.8M | $37.3M | $224.5M | $149.1M | $39.1M | |
| Marketable Securities | $58.1M | $81.7M | $162.9M | $210.8M | $307.8M | $427.3M | $386.2M | $386.6M | $502.9M | $518.1M | $541.7M | |
| Total Current Assets | $68.8M | $94.6M | $181.2M | $239.6M | $637.3M | $522.3M | $446.4M | $432.5M | $744.8M | $708.7M | $623.8M | |
| Total Assets | $69.8M | $95.9M | $182.4M | $242.0M | $647.2M | $534.1M | $456.3M | $448.9M | $760.2M | $738.4M | $652.6M | |
| Total Current Liabilities | $5.5M | $10.0M | $13.6M | $15.6M | $26.0M | $22.5M | $24.1M | $35.3M | $78.7M | $117.0M | $101.5M | |
| Long-Term Debt | $7.3M | $5.6M | $7.5M | $7.3M | $4.3M | $0.00 | $9.2M | $9.3M | $6.9M | $9.7M | $9.7M | |
| Total Liabilities | $12.9M | $16.0M | $21.4M | $23.2M | $36.3M | $27.4M | $36.0M | $51.7M | $346.5M | $564.2M | $544.7M | |
| Stockholders' Equity | $56.9M | $79.9M | $161.0M | $218.8M | $610.9M | $506.6M | $420.3M | $397.3M | $413.6M | $174.1M | $107.9M | |
| Retained Earnings | $-53.9M | $-89.3M | $-149.7M | $-212.9M | $-302.5M | $-433.0M | $-568.8M | $-721.4M | $-895.4M | $-1.17B | $-1.25B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-25.3M | $-28.4M | $-48.7M | $-54.8M | $-69.8M | $-104.6M | $-110.1M | $-124.8M | $134.3M | $-64.1M | $-78.0M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $-2.2M | $-1.1M | $-626.0K | $-168.0K | $-472.0K | $-6.6M | $-6.5M | |
| Free Cash Flow | $-25.3M | $-28.4M | $-48.7M | $-54.8M | $-72.0M | $-105.7M | $-110.7M | $-125.0M | $133.8M | $-70.7M | $-84.5M | |
| Investing Cash Flow | $12.2M | $-23.4M | $-79.3M | $-46.3M | $-99.9M | $-126.8M | $32.6M | $15.6M | $-101.6M | $-13.1M | $64.1M | |
| Financing Cash Flow | $7.5M | $53.6M | $132.6M | $111.1M | $469.3M | $-3.4M | $38.6M | $94.8M | $154.4M | $1.8M | $1.7M | |
| Issuance of Stock | $0.00 | $53.7M | $132.2M | $108.2M | $459.3M | $0.00 | $24.7M | $93.6M | $145.8M | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $7.5M | $0.00 | $627.0K | $0.00 | $0.00 | $0.00 | $10.0M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $-344.0K | $-1.3M | $0.00 | $-250.0K | $-7.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.1M | $4.5M | $8.7M | $9.4M | $12.8M | $23.6M | $26.3M | $28.1M | $33.9M | $37.1M | $37.7M | |
| Net Change in Cash | $-5.7M | $1.7M | $4.7M | $10.0M | $299.6M | $-234.8M | $-38.9M | $-14.5M | $187.1M | $-75.4M | $-12.2M |
Dilution Tracker
Shares outstanding grew 33.5% over 5 years — significant dilution
Shares Outstanding
89M
5-Year Share Growth
+33.5%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 18.70 | 23.24 | 35.19 | 41.95 | 53.08 | 66.35 | 66.99 | 73.23 | 86.16 | 87.68 | 88.61 | |
| YoY Change % | — | 24.3% | 51.4% | 19.2% | 26.5% | 25.0% | 1.0% | 9.3% | 17.7% | 1.8% | 1.1% | |
| Stock Issuance | $0.00 | $53.7M | $132.2M | $108.2M | $459.3M | $0.00 | $24.7M | $93.6M | $145.8M | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.1M | $4.5M | $8.7M | $9.4M | $12.8M | $23.6M | $26.3M | $28.1M | $33.9M | $37.1M | $37.7M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 99.9% | 99.6% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -358.5% | -449.9% | -443.5% | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -322.9% | -412.9% | -411.2% | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -314.6% | -408.7% | -407.4% | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 248.4% | -104.8% | -117.9% | |
| ROE % | -39.7% | -51.8% | -50.2% | -33.3% | -21.6% | -23.3% | -29.3% | -37.3% | -42.9% | -94.8% | -123.3% | |
| ROA % | -35.1% | -42.8% | -43.5% | -29.8% | -20.2% | -22.1% | -27.4% | -33.7% | -28.8% | -37.2% | -42.5% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.41
P/S14.04
Historical5.81 / 10.18 / 14.13
Industry Med.9.51
P/B9.42
Historical1.25 / 3.46 / 9.42
Industry Med.2.93
EV/EBITDA-1.57
Historical-2.52 / -0.36 / 0.82
Industry Med.13.14
EV/Revenue6.41
Historical-2.14 / 1.27 / 6.41
Industry Med.8.71
P/FCF—
Historical3.92 / 5.22 / 12.59
Industry Med.27.54
Intrinsic Value Models
Tangible Book
$1.22
Net Current Assets
$0.890
Net-Net Working Capital
$0.49
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | - | - | - | 13.94 | 13.49 | 14.04 | |
| PB Ratio | 2.22 | 5.79 | 3.33 | 2.85 | 3.54 | 1.84 | 2.02 | 2.69 | 1.65 | 5.24 | 9.42 | |
| EV/EBITDA | -2.43 | -10.90 | -6.12 | -6.31 | -17.37 | -3.25 | -3.14 | -4.41 | 0.17 | -0.96 | -1.57 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.55 | 3.94 | 6.41 |
Analyst Estimates & Quality
Altman Z-Score
-1.97
Distress
Piotroski F-Score
1
Weak
Beneish M-Score
-4.62
Unlikely Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $92.39M | $187.21M | $246.55M |
| Net Income | $-315.14M | $-251.58M | $-202.98M |
| EPS | -3.34 | -2.67 | -2.07 |
| Book Value per Share | -1.18 | -4.06 | -4.28 |
| Operating Cash Flow per Share | -3.35 | -2.43 | -2.10 |
| Operating CF | $-296.55M | $-215.32M | $-186.08M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Discovery and development of precision medicines for the treatment of cancer | $67.5M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $67.5M |